Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31571147 | 1.00 | TGFBR1 (0.50) | TGFBR1RAB9AARMAPTKDM4E | |
| SCHEMBL26259560 | 0.87 | PDPK1 (0.54) | TGFBR1RAB9AARPDPK1CYP2A6 | |
| SCHEMBL26259375 | 0.79 | PDPK1 (0.59) | TGFBR1RAB9AARMAPTKDM4E | |
| SCHEMBL198641 | 0.79 | MAPT (0.64) | MAPTKDM4ECA12CA1CA2 | |
| 1-Naphthalenylthiazole SCHEMBL272929 | 0.79 | RAB9A (0.53) | TGFBR1RAB9AARMAPTKDM4E | |
| SCHEMBL20571767 | 0.76 | TGFBR1 (0.50) | TGFBR1RAB9AMAPTKDM4EPDPK1 | |
| SCHEMBL5692672 | 0.75 | PDPK1 (0.64) | TGFBR1RAB9APDPK1CYP2A6HSP90AA1 | |
| SCHEMBL31525616 | 0.74 | ECE1 (0.50) | TGFBR1RAB9AARMAPTKDM4E | |
| SCHEMBL7918743 | 0.74 | MAPT (0.56) | TGFBR1RAB9AMAPTKDM4ECA12 | |
| SCHEMBL27841121 | 0.74 | MAPT (0.56) | MAPTKDM4ECA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4472734-A1 | HETEROCYCLIC DERIVATIVES AS MALT1 INHIBITORS | C4X Discovery Limited (GB) | 2024-12-11 | — | — | EP | disclosed |
| WO-2023148501-A1 | HETEROCYCLIC DERIVATIVES AS MALT1 INHIBITORS | C4X DISCOVERY LIMITED (GB) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023148501-A1 | HETEROCYCLIC DERIVATIVES AS MALT1 INHIBITORS | C4X DISCOVERY LIMITED (GB) | 2023-08-10 | — | — | WO | disclosed |
| US-20210024464-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | UNIV BRITISH COLUMBIA (CA) | 2021-01-28 | — | — | US | disclosed |
| US-20210024464-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | UNIV BRITISH COLUMBIA (CA) | 2021-01-28 | — | — | US | disclosed |
| US-10633338-B2 | Binding Function 3 (BF3) site compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2020-04-28 | — | — | US | disclosed |
| US-10633338-B2 | Binding Function 3 (BF3) site compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2020-04-28 | — | — | US | disclosed |
| US-20190300480-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2019-10-03 | — | — | US | disclosed |
| US-20190300480-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2019-10-03 | — | — | US | disclosed |
| US-10351527-B2 | Binding function 3 (BF3) site compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2019-07-16 | — | — | US | disclosed |
| US-10351527-B2 | Binding function 3 (BF3) site compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2019-07-16 | — | — | US | disclosed |
| US-20170029372-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-02-02 | — | — | US | disclosed |
| US-20170029372-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-02-02 | — | — | US | disclosed |
| US-20170029372-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-02-02 | — | — | US | disclosed |
| WO-2015154169-A1 | BINDING FUNCTION3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-10-15 | — | — | WO | disclosed |
| WO-2015154169-A1 | BINDING FUNCTION3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300480-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | KLK3, SHBG, ACP3 | TGFBR1 3697/4885RAB9A 2978/4885AR 29/4885 |
| US-10633338-B2 | Binding Function 3 (BF3) site compounds as therapeutics and methods for their use | KLK3, SHBG, ACP3 | TGFBR1 3697/4885RAB9A 2978/4885AR 29/4885 |
| US-10351527-B2 | Binding function 3 (BF3) site compounds as therapeutics and methods for their use | KLK3, SHBG, ACP3 | TGFBR1 3697/4885RAB9A 2978/4885AR 29/4885 |
| US-20210024464-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | KLK3, SHBG, ACP3 | TGFBR1 3697/4885RAB9A 2978/4885AR 29/4885 |
| US-20170029372-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | KLK3, SHBG, ACP3 | TGFBR1 3697/4885RAB9A 2978/4885AR 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.